Literature DB >> 14679138

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

T Kurata, K Tamura, H Kaneda, T Nogami, H Uejima, G o Asai Go, K Nakagawa, M Fukuoka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14679138     DOI： 10.1093/annonc/mdh006

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  30 in total

1.  Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

Authors:  Zhengbo Song; Xinmin Yu; Chunxiao He; Beibei Zhang; Yiping Zhang
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 2.  Drug rechallenge and treatment beyond progression--implications for drug resistance.

Authors:  Elizabeth A Kuczynski; Daniel J Sargent; Axel Grothey; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

3.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

4.  A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Authors:  Sarah B Goldberg; Jeffrey G Supko; Joel W Neal; Alona Muzikansky; Subba Digumarthy; Panos Fidias; Jennifer S Temel; Rebecca S Heist; Alice T Shaw; Patricia O McCarthy; Thomas J Lynch; Sreenath Sharma; Jeffrey E Settleman; Lecia V Sequist
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 5.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

Review 6.  Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.

Authors:  Margarita Majem; Jordi Remon
Journal:  Transl Lung Cancer Res       Date:  2013-06

Review 7.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

8.  Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Authors:  Luping Lin; Trever G Bivona
Journal:  Chemother Res Pract       Date:  2012-08-29

9.  Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.

Authors:  Pan-Yu Chen; Mandar Deepak Muzumdar; Kimberly Judith Dorans; Rebecca Robbins; Arjun Bhutkar; Amanda Del Rosario; Philipp Mertins; Jana Qiao; Anette Claudia Schafer; Frank Gertler; Steven Carr; Tyler Jacks
Journal:  Cancer Res       Date:  2017-12-26       Impact factor: 12.701

10.  Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Authors:  D J E Peeters; B De Laere; G G Van den Eynden; S J Van Laere; F Rothé; M Ignatiadis; A M Sieuwerts; D Lambrechts; A Rutten; P A van Dam; P Pauwels; M Peeters; P B Vermeulen; L Y Dirix
Journal:  Br J Cancer       Date:  2013-03-07       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.